Neuren Pharmaceuticals Limited
14
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
84.6%
-1.9% vs industry average
7%
1 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Role: lead
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Role: lead
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
Role: lead
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Role: lead
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Role: lead
To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers
Role: lead
A Safety Study of NNZ-2566 in Pediatric Rett Syndrome
Role: lead
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
Role: lead
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
Role: lead
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
Role: lead
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
Role: lead
Study of NNZ-2566 in Patients With Traumatic Brain Injury
Role: lead
Safety Study of NNZ-2566 in Healthy Female Subjects
Role: lead
Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration
Role: lead
All 14 trials loaded